[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349777-105":59,"doc-detail-349777-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mitoxantrone-alters-cd24siglec-10-expression-in-malignant-brain-tumor-models","Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models","","Mitoxantrone modulates the CD24/Siglec-10 axis in malignant brain tumor contexts, targeting an immune-evasion interaction that links tumor cells to tumor-associated macrophages and microglia. CD24 gene expression associates with prognosis-related gene signatures in medulloblastoma and glioblastoma, while Siglec-10+ cells co-express TREM2. Treatment with mitoxantrone reduces cell viability and surface CD24, and intratumoral dosing in a CD24-high glioma model extends survival, shrinks tumors, shifts immune infiltrates, and decreases Siglec-10+/TREM2+ populations while enhancing anti-tumor CD8+ cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mitoxantrone-alters-cd24siglec-10-expression-in-malignant-brain-tumor-models/349777/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mitoxantrone-alters-cd24siglec-10-expression-in-malignant-brain-tumor-models/349777.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the biological relationship between CD24 and Siglec-10 in malignant brain tumors?","Question",{"text":112,"@type":113},"CD24 on tumor cells interacts with Siglec-10, expressed on immune cells, promoting immune evasion through an immunosuppressive tumor environment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do in silico analyses suggest about CD24 in medulloblastoma and glioblastoma?",{"text":117,"@type":113},"CD24 expression correlates with gene signatures associated with prognosis in both medulloblastoma and glioblastoma.",{"name":119,"@type":110,"acceptedAnswer":120},"How does mitoxantrone affect tumor outcome and immune cell populations in the CD24-high glioma model?",{"text":121,"@type":113},"Intratumoral mitoxantrone administration extends survival, decreases tumor size, reduces Siglec-10+/TREM2+ cells, and increases anti-tumor CD8+ cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349777,1790154913,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models  \nJan Kopecky1,9, Julio Enríquez Pérez1,9, Stevanus Jonathan1, Tom Milos1, Poi Kwanyuen1, Julia Biskupiak1, Edward Visse1, Kelin Gonçalves De Oliveira2, Hugo Talbot2,  \nMyriam Cerezo-Magaña2, Valeria Governa2, Jinquan Cai3, Marie Arsenian Henriksson3,4, Nils Ståhl7, David Cederberg7, Mattias Belting2,5,6, Peter Siesjö1,7 & Anna Darabi1,8􀀍  \nMedulloblastoma and glioblastoma are the most common malignant primary brain tumors in children and adults, respectively. Tumor-associated macrophages and microglia are key non-cancerous cell types in these tumors. These cells interact with CD24, a so called “don’t eat me signal” expressed on tumor cells, through Siglec-10, a receptor that contributes to immune evasion by promoting an immunosuppressive environment. The CD24/Siglec-10 interaction in context of malignant brain tumors has been scarcely studied.In silico analyses reveal that CD24 gene expression correlates with specific gene signatures associated with prognosis in both medulloblastoma and glioblastoma. In both human-and mouse brain tumors, Siglec-10+ cells co-express the microglia-associated molecule TREM2 . Treatment with mitoxantrone as an immunogenic cell-death-inducing cytostatic agent led to a dosedependent reduction in cell viability and cell surface CD24 levels in both murine and human brain tumor cell cultures. Intratumoral mitoxantrone administration in a murine CD24-high glioma model extended survival, decreased tumor size, reduced Siglec-10+/TREM2+ cell populations, and increased anti-tumor CD8+ cells. These findings suggest that targeting the CD24/Siglec-10 axis with mitoxantrone may modulate the tumor microenvironment and enhance anti-tumor immunity. Keywords: CD24, Siglec-10, Mitoxantrone, Malignant brain tumor, Immunotherapy.  \nAbbreviations:  \nMB: medulloblastoma.  \nGBM: glioblastoma.  \nCNS: central nervous system.  \nC: classical.  \nM: mesenchymal.  \nPN: proneural.  \nIDHmut: isocitrate dehydrogenase mutant.  \nWHO: World Health Organization.  \nSHH: sonic hedgehog.  \nTAMs: tumor-associated macrophages and microglia.  \nICI: immune checkpoint inhibitors.  \nMTX: mitoxantrone.  \nICD: immunogenic cell death.  \nATP: adenosine triphosphate.  \nHMGB1: high mobility group box-1 .  \nBMDM: bone-marrow-derived macrophages.  \nMG: microglia.  \n1Department of Clinical Sciences Lund, Neurosurgery, Lund University, Lund, Sweden. 2Department of Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden. 3Department of Microbiology, Tumor and Cell Biology, Biomedicum B7, Karolinska Institutet, Stockholm, Sweden. 4Department of Laboratory Medicine, Translational Cancer Research, Lund University, Lund, Sweden. 5Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 6Department of Hematology, Oncology, and Radiation physics, Skåne University Hospital, Lund, Sweden. 7Department of Neurosurgery, Skåne University Hospital, Lund, Sweden. 8Glioma Immunotherapy Group, Barngatan 4, Lund 221-85, Sweden. 9Shared first authorship: Jan Kopecky and Julio Enríquez Pérez. 􀀍 email: [anna.darabi@med.lu.se](anna.darabi@med.lu.se)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nhMB: human MB.  \nhGBM: human GBM.  \nIntroduction  \nMedulloblastoma (MB) is the most common malignant brain tumor in young children, with a 5-year (5y) survival rate of about 70%, though infants face an even poorer prognosis1. Glioblastoma (GBM) is the most prevalent malignant brain tumor in adults, with a dismal 5y survival rate of 3–6%1,2. In children, GBM is rare and has a 5y survival rate of less than 20%3. Current standard treatments, including maximal surgical resection, radiation, and chemotherapy, lead to severe side effects in children and only marginally extend survival in adults2,4. Brain tumor entities can be further div","cbCaimJlufSbRJwX","https://ap.wps.com/l/cbCaimJlufSbRJwX","pdf",12298872,18,"English","# Introduction\n## Epidemiology and clinical need\n## Molecular subgrouping of medulloblastoma and glioblastoma\n## Immune suppression and tumor microenvironment\n# Immune checkpoint blockade context\n## Limitations of current ICI approaches","[{\"question\":\"What is the biological relationship between CD24 and Siglec-10 in malignant brain tumors?\",\"answer\":\"CD24 on tumor cells interacts with Siglec-10, expressed on immune cells, promoting immune evasion through an immunosuppressive tumor environment.\"},{\"question\":\"What do in silico analyses suggest about CD24 in medulloblastoma and glioblastoma?\",\"answer\":\"CD24 expression correlates with gene signatures associated with prognosis in both medulloblastoma and glioblastoma.\"},{\"question\":\"How does mitoxantrone affect tumor outcome and immune cell populations in the CD24-high glioma model?\",\"answer\":\"Intratumoral mitoxantrone administration extends survival, decreases tumor size, reduces Siglec-10+/TREM2+ cells, and increases anti-tumor CD8+ cells.\"}]","Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models | PDF",1790085521,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b003ae232cf32db3d14b92e1ea7a9eb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1097681daf3269dfb084c8090fc23a5.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01116c8aa7e7c6f89dedc8fb95427fd3.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8583afddb9e1cc79922ca2025951248.webp",980,1287]